Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

We recently published a list of 10 Stocks Got Wiped Out. Are You Holding Any? In this article, we are going to take a look at ...

Hims & Hers Health, Inc. HIMS announced that eligible customers can now access six months of prescription-only Wegovy at a ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Hims & Hers beat first-quarter profit and revenue forecasts as sales more than doubled. However, the health and wellness platform missed analysts' estimates for current-quarter sales on the impact of ...

Telemedicine company Hims & Hers has hired Farshad Shadloo to lead communications. As VP of communications, Shadloo reports ...

Online health and wellness company Hims & Hers raised $1 billion through convertible senior notes to grow its international ...

Looking back on healthcare technology stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Hims & Hers Health (NYSE:HIMS) and its peers.

Health and wellness company, which sold alternatives to weight-loss drugs like Wegovy, is now collaborating with Wegovy-maker Novo Nordisk.